The maker of EpiPen has agreed to pay the government $465 million after overcharging for the medicine

Mylan, the marker of the EpiPen, has agreed to pay the federal government a $465 million settlement after it overcharged government healthcare agencies for the medicine, according to a release from the firm.

Mylan had underpaid Medicare and Medicaid by classifying the EpiPen as a generic drug. Generic drugs are subject to a 13% rebate from the marker to Medicaid and Medicare, rather than a 23.1% rebate for brand name drugs.

Following the news, shares of Mylan had jumped nearly 8% in after-hours trading to $38.75 per share.

More to come…

NOW WATCH: FEMA is tracking Hurricane Matthew using the ‘Waffle House Index’

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at